ESMO 2026 to Highlight Advances in Rectal and Prostate Cancer
The 2026 European Society for Medical Oncology congress is scheduled for October 23–27. Experts expect important trial results in rectal, prostate, and other cancers that could alter clinical practice.
The ESMO 2026 congress is scheduled for October 23–27, with attention expected on rectal and prostate cancer research. The summary indicates that important trial results in these and other cancers could alter clinical practice, making the meeting a notable point for new evidence in oncology.
If trial results presented at ESMO 2026 prove practice-changing, patients with rectal and prostate cancer could be affected through shifts in treatment discussions and clinical decision-making. Clinicians and health systems may also need to interpret and adopt new evidence carefully. The broader public impact would depend on how robust and applicable the findings are, so the meeting’s influence may be gradual rather than immediate.